China Foods' Revenue Soars 378%, But Losses Persist Amid Rising Debt

TL;DR

**CFOO's revenue jump is a mirage; mounting debt and persistent losses make it a high-risk bet, avoid.**

AI Summary

China Foods Holdings Ltd. (CFOO) reported a significant increase in revenue for the nine months ended September 30, 2025, reaching $239,083, a substantial rise from $50,020 in the same period of 2024, primarily driven by a surge in healthcare product sales to $238,661 from $3,378. Despite this revenue growth, the company's net loss widened to $280,153 for the nine months ended September 30, 2025, compared to a net loss of $297,132 in the prior year, indicating persistent profitability challenges. The gross profit increased to $24,455 from $21,491 year-over-year. Operating expenses remained high at $304,807 for the nine months ended September 30, 2025, slightly down from $318,454 in 2024, with general and administrative expenses being the largest component at $299,661. The company's total assets decreased to $281,642 as of September 30, 2025, from $435,005 at December 31, 2024, while total current liabilities increased to $1,430,374 from $1,285,812, exacerbating its stockholders' deficit to $(1,148,732) from $(850,807). Cash and cash equivalents increased to $76,861 from $39,192, largely due to $311,714 in financing activities, including advances from directors and related parties.

Why It Matters

This filing reveals a company struggling to translate significant revenue growth in healthcare products into profitability, with a widening net loss and a growing stockholders' deficit. For investors, the increasing reliance on related party financing, with 'Amount due to directors' at $449,202 and 'Amount due to a related company' at $359,633, raises concerns about financial independence and potential conflicts of interest. Employees and customers might face uncertainty given the company's precarious financial health and negative equity. In a competitive health and wellness market, CFOO's inability to achieve positive net income despite revenue expansion suggests fundamental operational or pricing challenges that could impact its long-term viability and market position.

Risk Assessment

Risk Level: high — The company exhibits a high risk level due to a significant stockholders' deficit of $(1,148,732) as of September 30, 2025, worsening from $(850,807) at December 31, 2024. Furthermore, total current liabilities of $1,430,374 far exceed total current assets of $250,545, indicating severe liquidity issues and a reliance on related party financing, with $449,202 due to directors and $359,633 due to a related company.

Analyst Insight

Investors should exercise extreme caution and consider divesting any holdings in CFOO. The company's substantial and growing stockholders' deficit, coupled with its reliance on related party financing and inability to achieve profitability despite revenue growth, signals significant financial instability and high investment risk.

Financial Highlights

debt To Equity

N/A

revenue

$239,083

operating Margin

N/A

total Assets

$281,642

total Debt

N/A

net Income

$(280,153)

eps

N/A

gross Margin

10.2%

cash Position

$76,861

revenue Growth

+378%

Revenue Breakdown

Key Numbers

• $239,083 — Revenue, net (Increased from $50,020 in 2024 for the nine months ended September 30, 2025, a 378% increase.)
• $(280,153) — Net Loss (For the nine months ended September 30, 2025, compared to $(297,132) in 2024, indicating persistent unprofitability.)
• $(1,148,732) — Total Stockholders' Deficit (Worsened from $(850,807) at December 31, 2024, highlighting severe negative equity.)
• $1,430,374 — Total Current Liabilities (Increased from $1,285,812 at December 31, 2024, significantly exceeding current assets.)
• $250,545 — Total Current Assets (Decreased from $398,686 at December 31, 2024, indicating declining liquidity.)
• $449,202 — Amount due to directors (Increased from $360,858 at December 31, 2024, showing growing reliance on insider financing.)
• $311,714 — Net cash provided by financing activities (For the nine months ended September 30, 2025, crucial for maintaining cash balance.)
• $76,861 — Cash and cash equivalents (Increased from $39,192 at the beginning of the period, primarily due to financing activities.)
• $238,661 — Sales of healthcare products (Major revenue driver, up from $3,378 in 2024 for the nine months ended September 30, 2025.)
• $422 — Sales of wine products (Significantly decreased from $46,642 in 2024 for the nine months ended September 30, 2025.)

Key Players & Entities

• China Foods Holdings Ltd. (company) — registrant
• SEC (regulator) — filing authority
• $239,083 (dollar_amount) — revenue for nine months ended September 30, 2025
• $50,020 (dollar_amount) — revenue for nine months ended September 30, 2024
• $280,153 (dollar_amount) — net loss for nine months ended September 30, 2025
• $297,132 (dollar_amount) — net loss for nine months ended September 30, 2024
• $1,148,732 (dollar_amount) — total stockholders' deficit as of September 30, 2025
• $449,202 (dollar_amount) — amount due to directors as of September 30, 2025
• $359,633 (dollar_amount) — amount due to a related company as of September 30, 2025
• Guangzhou Xiao Xiang Health Industry Company Limited (company) — subsidiary in PRC

FAQ

Risk Factors

• Persistent Net Losses and Widening Deficit [high — financial]: The company continues to incur substantial net losses, with the net loss widening to $280,153 for the nine months ended September 30, 2025, from $297,132 in the prior year. This, coupled with a worsening stockholders' deficit to $(1,148,732), indicates ongoing profitability challenges and a precarious financial position.
• Increasing Reliance on Related Party Financing [high — financial]: The amount due to directors has increased to $449,202 from $360,858, and financing activities, including advances from directors and related parties, were crucial in boosting cash to $76,861. This growing dependence on insider financing raises concerns about financial independence and potential conflicts of interest.
• Deteriorating Liquidity and Solvency [high — financial]: Total current liabilities have increased to $1,430,374, significantly exceeding total current assets of $250,545. This widening gap, along with a decrease in total assets to $281,642, points to deteriorating liquidity and solvency, increasing the risk of short-term financial distress.
• Over-reliance on a Single Product Segment [medium — operational]: The dramatic increase in revenue is almost entirely attributable to healthcare product sales ($238,661), while wine product sales have plummeted ($422). This over-reliance on a single segment makes the company vulnerable to market shifts, competition, or regulatory changes affecting healthcare products.
• High Operating Expenses [medium — operational]: Despite a slight decrease, operating expenses remain high at $304,807, with general and administrative expenses constituting the largest portion ($299,661). These high costs, relative to gross profit ($24,455), contribute to the company's unprofitability.

Industry Context

The company operates in sectors that have seen significant shifts, particularly with the surge in healthcare product demand. However, the sharp decline in wine product sales suggests a challenging environment for traditional offerings. The broader market may be experiencing a bifurcation, with strong growth in health-related sectors contrasting with potential contraction in others.

Regulatory Implications

While specific regulatory risks are not detailed in this excerpt, the significant reliance on healthcare product sales could expose the company to evolving regulations within that industry. Furthermore, the substantial related-party transactions may attract scrutiny regarding corporate governance and disclosure requirements.

What Investors Should Do

1. Monitor the sustainability of healthcare product sales growth and assess competitive pressures in this segment.
2. Investigate the reasons behind the drastic decline in wine product sales and evaluate the viability of this segment.
3. Analyze the company's strategy for addressing its persistent net losses and widening stockholders' deficit.
4. Assess the long-term implications of the increasing reliance on director and related party financing.
5. Evaluate the company's ability to manage its high operating expenses and improve overall profitability.

Key Dates

• 2025-09-30: Nine months ended — Period for which the reported financial results (revenue surge, widened net loss, increased liabilities) are presented.
• 2024-12-31: As of — Balance sheet comparison point for assets, liabilities, and stockholders' deficit.
• 2024-09-30: Nine months ended — Prior year period for comparison of revenue, net loss, and operating expenses.

Glossary

Stockholders' Deficit

A negative stockholders' equity, meaning the company's liabilities exceed its assets. (Indicates severe negative equity for CFOO, worsening to $(1,148,732).)

Current Liabilities

Obligations that are expected to be paid within one year or one operating cycle, whichever is longer. (CFOO's current liabilities increased to $1,430,374, highlighting short-term financial pressure.)

Financing Activities

Cash flows related to debt, equity, and dividends. (Net cash from financing activities of $311,714 was crucial for CFOO's cash balance, primarily from director advances.)

General and Administrative Expenses

Costs associated with the overall management and administration of a business, not directly tied to production or sales. (These expenses were the largest component of CFOO's operating expenses at $299,661.)

Gross Profit

Revenue minus the cost of goods sold. (CFOO's gross profit increased to $24,455, but remains low relative to operating expenses.)

Year-Over-Year Comparison

Revenue has seen a dramatic increase of 378% to $239,083, primarily driven by a massive surge in healthcare product sales. However, this top-line growth has not translated into improved profitability, as the net loss has widened slightly to $280,153. Total assets have decreased, while current liabilities have increased, leading to a significantly worsened stockholders' deficit. Cash position has improved, but this is largely due to increased financing from related parties, highlighting a continued precarious financial situation.

Key Financial Figures

• $0.66 — t's shares were last sold at a price of $0.66 per share. Although the Registrant's st
• $863,939.05 — affiliates would have a market value of $863,939.05. As of November 10, 2025, the Registr
• $0.0001 — spectively 2,025 2,025 Common stock $0.0001 par value, 100,000,000 shares authorize
• $ — rrency is not US$ are translated into US$, in accordance with ASC Topic 830-30, "

Filing Documents

• form10-q.htm (10-Q) — 748KB
• ex31-1.htm (EX-31.1) — 12KB
• ex32-1.htm (EX-32.1) — 5KB
• 0001493152-25-023218.txt ( ) — 4200KB
• cfoo-20250930.xsd (EX-101.SCH) — 30KB
• cfoo-20250930_cal.xml (EX-101.CAL) — 49KB
• cfoo-20250930_def.xml (EX-101.DEF) — 101KB
• cfoo-20250930_lab.xml (EX-101.LAB) — 232KB
• cfoo-20250930_pre.xml (EX-101.PRE) — 186KB
• form10-q_htm.xml (XML) — 719KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1. Unaudited Condensed Consolidated Financial Statements 3 Notes to Unaudited Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 25 Item 4.

Controls and Procedures

Controls and Procedures 25

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 26 Item 1A.

Risk Factors

Risk Factors 26 Item 2. Unregistered Sales of Equity Securities and Proceeds 26 Item 3. Defaults Upon Senior Securities 26 Item 4. Mine Safety Disclosure 26 Item 5. Other Information 26 Item 6. Exhibits 26

SIGNATURES

SIGNATURES 27 2 PART I – FINANCIAL INFORMATION Item 1. Financial Statements China Foods Holdings Ltd. Unaudited Condensed Consolidated Balance Sheets (Currency expressed in United States Dollars ("US

View Full Filing

View this 10-Q filing on SEC EDGAR